Screening High-Risk Groups and the General Population for SARS-CoV-2 Nucleic Acids in a Mobile Biosafety Laboratory

Abstract

The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has challenged public health systems worldwide. Therefore, large-scale testing capacity is extremely important diagnosis and exclusion diagnosis. However, fixed laboratories are limited or far away from remote areas. Fortunately, MBS-Lab is characterized by high mobility and rapid on-site detection of SARS-CoV-2 nucleic acid. MBS-Lab was first used in northern Australia during a melioidosis outbreak in 1997. The MBS-Lab and a well-trained diagnostic team were dispatched to Dongchang District, Tonghua City, Jilin Province, China to assist the SARS-CoV-2 virus screening and diagnosis on January 17, 2021. Altogether, 93,952 oropharyngeal swabs samples were collected and tested among the high-risk groups and the general population in Dongchang District. Two single samples were identified as positive in the second turn screening. In the second turn screening, 3 mixed samples (10 in 1) were identified as positive; 10 mixed samples were identified as positive in the third turn screening. By resampling again, one and four cases were identified as positive, respectively. The positive cases were properly isolated and treated in hospital and avoided to visit family members, friends, colleagues and any other persons. Through this way of large-scale screening, human-human spread of SARS-CoV-2 can be effectively avoided. In addition, all staff members strictly executed multiple safety precautions and reduce exposure risks. In the end, none of the staffs was infected with SARS-CoV-2 virus or other pathogens. As an emergency facility for infectious disease control, the MBS-Lab satisfies the requirements of ports and other remote areas far from fixed laboratories and supplements the capabilities of fixed laboratories.

Keywords: SARS-CoV-2; bio-protection; mobile biosafety laboratory; nucleic acid; real-time PCR.